How to buy Sesen Bio stock (SESN)

Sesen Bio is a biotechnology business based in the US. Sesen Bio shares (SESN) are listed on the NASDAQ and all prices are listed in US Dollars. Sesen Bio employs 17 staff and has a trailing 12-month revenue of around $40 million.

Our top picks for where to buy Sesen Bio stock

Buy Sesen Bio stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Sesen Bio stock price (NASDAQ: SESN)

Use our graph to track the performance of SESN stocks over time.

Sesen Bio shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$0.60
200-day moving average more info button	$0.62
Wall St. target price	$12.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-0.10

Is it a good time to buy Sesen Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sesen Bio financials

Revenue TTM	$40 million
Gross profit TTM	$38 million
Return on assets TTM	-11.16%
Return on equity TTM	-12.06%
Profit margin	-49.71%
Book value	$0.78
Market Capitalization more info button	$128 million

TTM: trailing 12 months

Sesen Bio share dividends

We're not expecting Sesen Bio to pay a dividend over the next 12 months.

Have Sesen Bio's shares ever split?

Sesen Bio's shares were split on a 1:20 basis on 7 March 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sesen Bio shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Sesen Bio shares which in turn could have impacted Sesen Bio's share price.

Sesen Bio share price volatility

Over the last 12 months, Sesen Bio's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sesen Bio's is 0.8295. This would suggest that Sesen Bio's shares are less volatile than average (for this exchange).

Sesen Bio overview

Sesen Bio, Inc. , a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc.

Frequently asked questions

What percentage of Sesen Bio is owned by insiders or institutions?
Currently 8.982% of Sesen Bio shares are held by insiders and 16.01% by institutions. How many people work for Sesen Bio?
Latest data suggests 17 work at Sesen Bio. When does the fiscal year end for Sesen Bio?
Sesen Bio's fiscal year ends in December. Where is Sesen Bio based?
Sesen Bio's address is: 245 First Street, Cambridge, MA, United States, 02142 What is Sesen Bio's ISIN number?
Sesen Bio's international securities identification number is: US8177631053 What is Sesen Bio's CUSIP number?
Sesen Bio's Committee on Uniform Securities Identification Procedures number is: 817763105